
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Equities research analysts at HC Wainwright decreased their FY2026 earnings per share estimates for Ionis Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($3.44) per share for the year, down from their prior estimate of ($3.41). HC Wainwright currently has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.57) per share. HC Wainwright also issued estimates for Ionis Pharmaceuticals’ Q4 2026 earnings at ($1.52) EPS, Q1 2027 earnings at ($1.09) EPS, Q2 2027 earnings at ($0.90) EPS, Q3 2027 earnings at ($0.10) EPS and FY2027 earnings at ($1.94) EPS.
Other equities research analysts also recently issued research reports about the company. Guggenheim dropped their price objective on Ionis Pharmaceuticals from $80.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday. BMO Capital Markets raised shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $54.00 to $66.00 in a report on Thursday, October 22nd. Canaccord Genuity Group dropped their target price on Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, September 8th. Royal Bank Of Canada dropped their price target on Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 10th. Finally, JPMorgan Chase & Co. cut their price target on shares of Ionis Pharmaceuticals from $76.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 22nd. Nineteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $75.00.
Read Our Latest Stock Analysis on IONS
Ionis Pharmaceuticals Stock Down 0.7%
Ionis Pharmaceuticals stock opened at $27.21 on Friday. The company has a quick ratio of 5.36, a current ratio of 5.43 and a debt-to-equity ratio of 3.42. The firm has a market cap of $4.53 billion, a P/E ratio of -8.20 and a beta of 0.43. The business has a fifty day moving average of $41.31 and a two-hundred day moving average of $63.46. Ionis Pharmaceuticals has a twelve month low of $26.55 and a twelve month high of $86.74.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The business had revenue of $242.72 million during the quarter, compared to analyst estimates of $178.17 million. During the same period in the previous year, the company posted ($0.80) EPS. Ionis Pharmaceuticals’s revenue was up 54.8% on a year-over-year basis.
Institutional Investors Weigh In On Ionis Pharmaceuticals
Several institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC lifted its position in shares of Ionis Pharmaceuticals by 7.4% in the second quarter. Integrated Wealth Concepts LLC now owns 2,926 shares of the company’s stock valued at $232,000 after acquiring an additional 202 shares in the last quarter. HighTower Advisors LLC grew its stake in Ionis Pharmaceuticals by 7.6% during the 2nd quarter. HighTower Advisors LLC now owns 4,084 shares of the company’s stock valued at $324,000 after acquiring an additional 287 shares in the last quarter. Grandfield & Dodd LLC grew its stake in Ionis Pharmaceuticals by 0.9% during the 3rd quarter. Grandfield & Dodd LLC now owns 37,396 shares of the company’s stock valued at $1,670,000 after acquiring an additional 319 shares in the last quarter. North Dakota State Investment Board raised its holdings in Ionis Pharmaceuticals by 7.1% in the 3rd quarter. North Dakota State Investment Board now owns 5,035 shares of the company’s stock valued at $225,000 after acquiring an additional 332 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in Ionis Pharmaceuticals by 6.4% in the 3rd quarter. ProShare Advisors LLC now owns 5,762 shares of the company’s stock valued at $257,000 after acquiring an additional 345 shares during the last quarter. 93.86% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, EVP Shannon L. Devers sold 1,357 shares of the stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $43.54, for a total transaction of $59,083.78. Following the transaction, the executive vice president owned 17,811 shares in the company, valued at $775,490.94. This trade represents a 7.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden acquired 5,000 shares of Ionis Pharmaceuticals stock in a transaction on Tuesday, November 10th. The shares were bought at an average price of $29.64 per share, with a total value of $148,200.00. Following the completion of the transaction, the director directly owned 27,000 shares of the company’s stock, valued at $800,280. This trade represents a 22.73% increase in their position. The disclosure for this purchase is available in the SEC filing. 1.81% of the stock is owned by company insiders.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Read More
- Five stocks we like better than Ionis Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
